CareDx, Inc. (NASDAQ:CDNA – Get Free Report) CFO Keith Kennedy sold 2,097 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $79.29, for a total transaction of $166,271.13. Following the completion of the sale, the chief financial officer directly owned 199,147 shares of the company’s stock, valued at $15,790,365.63. This trade represents a 1.04% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Keith Kennedy also recently made the following trade(s):
- On Thursday, November 5th, Keith Kennedy sold 61,961 shares of CareDx stock. The shares were sold at an average price of $77.82, for a total transaction of $4,821,805.02.
CareDx Stock Performance
CDNA stock opened at $73.72 on Tuesday. The firm has a market cap of $3.87 billion, a P/E ratio of 120.92 and a beta of 2.51. The firm’s fifty day moving average is $66.80 and its 200 day moving average is $36.97. CareDx, Inc. has a 52 week low of $15.15 and a 52 week high of $90.87.
CareDx (NASDAQ:CDNA – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.45. CareDx had a net margin of 25.86% and a return on equity of 9.74%. The business had revenue of $139.36 million during the quarter, compared to the consensus estimate of $121.96 million. During the same period in the previous year, the firm posted $0.03 earnings per share. The firm’s revenue for the quarter was up 39.3% on a year-over-year basis. As a group, analysts forecast that CareDx, Inc. will post 1.00 EPS for the current year.
Institutional Investors Weigh In On CareDx
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in CareDx during the 2nd quarter valued at $137,219,000. Goldman Sachs Group Inc. grew its holdings in CareDx by 33.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 931,678 shares of the company’s stock worth $60,559,000 after acquiring an additional 231,685 shares during the last quarter. Bamco Inc. NY bought a new stake in CareDx in the 2nd quarter worth $55,214,000. Amova Asset Management Americas Inc. increased its position in shares of CareDx by 2.0% in the first quarter. Amova Asset Management Americas Inc. now owns 1,475,126 shares of the company’s stock valued at $25,608,000 after acquiring an additional 28,510 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of CareDx by 11.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,461,914 shares of the company’s stock valued at $25,375,000 after acquiring an additional 151,934 shares during the period.
Wall Street Analyst Weigh In
CDNA has been the topic of several analyst reports. Weiss Ratings upgraded CareDx from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Wall Street Zen lowered CareDx from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 31st. Canaccord Genuity Group set a $99.00 target price on CareDx in a report on Friday, October 30th. Zacks Research upgraded CareDx from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 5th. Finally, Craig Hallum upgraded CareDx from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $70.33.
Get Our Latest Stock Analysis on CDNA
CareDx Company Profile
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
See Also
- Five stocks we like better than CareDx
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
